Product
MAM01
Aliases
MAM01 5 mg/kg
1 clinical trial
1 indication
Indication
MalariaClinical trial
A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive AdultsStatus: Recruiting, Estimated PCD: 2025-03-01